Skip to content
Med Pharma News

Med Pharma News

Your Daily Dose of Pharma News

  • About Med Pharma News
  • Contact Us
  • News
  • Privacy Policy
  • Terms and Conditions
Novartis sales growth guidance infographic: 5% CAGR to 2031, Kesimpta $8bn peak, 40% margin by 2029
  • Industry Insights
2 hours ago

Novartis Sales Growth Guidance: 5% a Year to 2031 as Kesimpta Peak Rises to $8B

Novartis guides to 5% annual sales growth through 2031, down from 5-6%, while raising peak sales for Kesimpta, Scemblix and Leqvio.

  • UnitedHealthcare Pharmacist Program: Independent Pharmacies Get Paid for Medicaid Care in 7 States
  • Pfizer Starna Deal: $330M Upfront Buys Into In Vivo CAR-T for Autoimmune Disease
  • Isomorphic Labs Series C: Inside the $5 Billion Record Bet on AI-Designed Drugs
FloLipid withdrawal FDA liquid statin infographic
  • Pharmaceuticals
6 hours ago6 hours ago

FloLipid Withdrawal: FDA Moves to Pull the First US Liquid Statin Over Missing Annual Reports

FDA has proposed withdrawing approval of Salerno Pharmaceuticals’ FloLipid simvastatin suspension after repeated missing annual reports. Hearing deadline 18 December.

  • Viatris Pacira Acquisition Closes: $1.65B Buys Exparel and a Non-Opioid Pain Franchise
  • NAC Supplement FDA Rule: Agency Moves to Make N-Acetylcysteine a Lawful Supplement After 6-Year Fight
  • Infilbray FDA Approval: Sanofi Pill Is First to Treat Brain Symptoms of Type 3 Gaucher Disease
Viatris Pacira acquisition infographic with $1.65 billion deal value and $36.50 per share price
  • Pharmaceuticals
7 hours ago7 hours ago

Viatris Pacira Acquisition Closes: $1.65B Buys Exparel and a Non-Opioid Pain Franchise

Viatris has closed its $1.65 billion, $36.50-a-share purchase of Pacira BioSciences, adding non-opioid pain drugs Exparel and Zilretta. Deal numbers, strategy and risks explained.

  • FloLipid Withdrawal: FDA Moves to Pull the First US Liquid Statin Over Missing Annual Reports
  • NAC Supplement FDA Rule: Agency Moves to Make N-Acetylcysteine a Lawful Supplement After 6-Year Fight
  • Infilbray FDA Approval: Sanofi Pill Is First to Treat Brain Symptoms of Type 3 Gaucher Disease
NAC supplement FDA rule infographic with timeline from 1963 drug approval to 2026 proposal
  • Pharmaceuticals
9 hours ago

NAC Supplement FDA Rule: Agency Moves to Make N-Acetylcysteine a Lawful Supplement After 6-Year Fight

FDA has proposed its first-ever rule declaring an ingredient not excluded from the supplement definition, clearing a path for NAC. What changes, what does not, and when.

  • FloLipid Withdrawal: FDA Moves to Pull the First US Liquid Statin Over Missing Annual Reports
  • Viatris Pacira Acquisition Closes: $1.65B Buys Exparel and a Non-Opioid Pain Franchise
  • Infilbray FDA Approval: Sanofi Pill Is First to Treat Brain Symptoms of Type 3 Gaucher Disease
  • Pharmaceuticals

Moderna and Merck Melanoma Vaccine Wins Phase 3. Regulators Are the Next Test

Megan Wood 2 hours ago
  • Pharmaceuticals

Merck Nemtabrutinib Discontinued: BELLWAVE CLL Program Ends After Safety Review

Megan Wood 2 hours ago
Novartis sales growth guidance infographic: 5% CAGR to 2031, Kesimpta $8bn peak, 40% margin by 2029
  • Industry Insights

Novartis Sales Growth Guidance: 5% a Year to 2031 as Kesimpta Peak Rises to $8B

Megan Wood2 hours ago09 mins

Novartis guides to 5% annual sales growth through 2031, down from 5-6%, while raising peak sales for Kesimpta, Scemblix and Leqvio.

Read More
FloLipid withdrawal FDA liquid statin infographic
  • Pharmaceuticals

FloLipid Withdrawal: FDA Moves to Pull the First US Liquid Statin Over Missing Annual Reports

Megan Wood6 hours ago6 hours ago010 mins

FDA has proposed withdrawing approval of Salerno Pharmaceuticals’ FloLipid simvastatin suspension after repeated missing annual reports. Hearing deadline 18 December.

Read More
Viatris Pacira acquisition infographic with $1.65 billion deal value and $36.50 per share price
  • Pharmaceuticals

Viatris Pacira Acquisition Closes: $1.65B Buys Exparel and a Non-Opioid Pain Franchise

Megan Wood7 hours ago7 hours ago010 mins

Viatris has closed its $1.65 billion, $36.50-a-share purchase of Pacira BioSciences, adding non-opioid pain drugs Exparel and Zilretta. Deal numbers, strategy and risks explained.

Read More
NAC supplement FDA rule infographic with timeline from 1963 drug approval to 2026 proposal
  • Pharmaceuticals

NAC Supplement FDA Rule: Agency Moves to Make N-Acetylcysteine a Lawful Supplement After 6-Year Fight

Megan Wood9 hours ago010 mins

FDA has proposed its first-ever rule declaring an ingredient not excluded from the supplement definition, clearing a path for NAC. What changes, what does not, and when.

Read More
UnitedHealthcare pharmacist program infographic: 7 Medicaid states, CPESN network in 47 states
  • Industry Insights

UnitedHealthcare Pharmacist Program: Independent Pharmacies Get Paid for Medicaid Care in 7 States

Megan Wood10 hours ago010 mins

UnitedHealthcare and CPESN USA will pay independent pharmacies for testing, chronic care and medication support for Medicaid members in seven states.

Read More
Infilbray FDA approval venglustat type 3 Gaucher disease infographic
  • Pharmaceuticals

Infilbray FDA Approval: Sanofi Pill Is First to Treat Brain Symptoms of Type 3 Gaucher Disease

Megan Wood12 hours ago010 mins

The FDA approved Sanofi’s Infilbray (venglustat), the first drug for neurological symptoms of type 3 Gaucher disease, after it beat enzyme therapy in the LEAP2MONO trial.

Read More
Pfizer Starna deal infographic showing $330M upfront, $2.3B milestones and three in vivo CAR-T autoimmune programs
  • Industry Insights

Pfizer Starna Deal: $330M Upfront Buys Into In Vivo CAR-T for Autoimmune Disease

Megan Wood14 hours ago011 mins

Pfizer is paying Starna Therapeutics $330 million upfront, with up to $2.3 billion in milestones, for three preclinical in vivo CAR-T programs in autoimmune disease. Terms, science and risks explained.

Read More
Merck nemtabrutinib discontinued infographic: three Phase 3 BELLWAVE CLL trials stopped
  • Pharmaceuticals

Merck Nemtabrutinib Discontinued: BELLWAVE CLL Program Ends After Safety Review

Megan Wood1 day ago09 mins

Merck ended all development of its non-covalent BTK inhibitor nemtabrutinib after a monitoring committee flagged benefit-risk concerns in Phase 3 BELLWAVE-011. The trials, the reasons and what comes next.

Read More
Isomorphic Labs Series C infographic: $5 billion round, $7.7 billion raised and AI drug discovery market growth
  • Industry Insights

Isomorphic Labs Series C: Inside the $5 Billion Record Bet on AI-Designed Drugs

Megan Wood1 day ago010 mins

Isomorphic Labs raised $5 billion in biotech’s largest private round. Who invested, how the money will be used and why clinical proof is still missing.

Read More
  • 1
  • 2
  • 3
  • …
  • 63

Categories

  • Healthcare IT (26)
  • Industry Insights (362)
  • Lifestyle and Wellness (24)
  • Medical Devices (45)
  • Pharmaceuticals (111)
  • Uncategorized (1)

Recent Posts

  • Novartis Sales Growth Guidance: 5% a Year to 2031 as Kesimpta Peak Rises to $8B
  • FloLipid Withdrawal: FDA Moves to Pull the First US Liquid Statin Over Missing Annual Reports
  • Viatris Pacira Acquisition Closes: $1.65B Buys Exparel and a Non-Opioid Pain Franchise
  • NAC Supplement FDA Rule: Agency Moves to Make N-Acetylcysteine a Lawful Supplement After 6-Year Fight
  • UnitedHealthcare Pharmacist Program: Independent Pharmacies Get Paid for Medicaid Care in 7 States

You May Have Missed

Fetal Monitoring Market
  • Industry Insights

Fetal Monitoring Market Revenue, Trends, and Strategic Insights by 2032

Megan Wood 9 months ago9 months ago
Veterinary Assistive Reproduction Technology Market
  • Industry Insights

Veterinary Assistive Reproduction Technology Market Revenue, Trends, and Strategic Insights by 2032

Megan Wood 9 months ago
Medtronic hypertension device: Symplicity Spyral outlook after SPYRAL AFFIRM results
  • Medical Devices

Medtronic Reports Significant Blood Pressure Reduction in SPYRAL AFFIRM Renal Denervation Study

Megan Wood 2 weeks ago
Intravenous Immunoglobulin Market
  • Industry Insights

Intravenous Immunoglobulin Market Revenue, Trends, and Strategic Insights by 2032

Megan Wood 7 months ago
BPaL TB regimen patent India graphic about generic market impact
  • Pharmaceuticals

BPaL TB Regimen Patent India: What the Rejection Means for Generic Makers and Procurement

Megan Wood 3 weeks ago
Graphic: magnifying glass over four tiles showing the HHS vaccine injury initiative moves, NIH clinic, CMS proposal, VAERS update and health records
  • Industry Insights

Kennedy Launches New Push on Vaccine Injuries: What HHS Revealed

Megan Wood 1 month ago1 month ago
DaVita Fresenius lawsuit infographic showing 51 DaVita and 29 Fresenius dialysis centres in Washington
  • Industry Insights

DaVita Fresenius Lawsuit: Washington Says Doctor Noncompetes Lock In Dialysis Monopolies

Megan Wood 1 week ago
Laurus Labs Q2 results graphic about CDMO mix and margins
  • Industry Insights

Laurus Labs Q2 Results: How CDMO Mix Drove a 126% Jump in Net Profit

Megan Wood 3 weeks ago
Digital Newspaper - Multipurpose News WordPress Theme 2026. Powered By BlazeThemes.